ITI-1000 Emerging Drug Insight and Market Forecast - 2032

ITI-1000 Emerging Drug Insight and Market Forecast − 2032

“ITI-1000 Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ITI-1000 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the ITI-1000 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ITI-1000 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ITI-1000 market forecast analysis for GBM in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

Immunomic Therapeutics (ITI) is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of shLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC Class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped sub-viral particle of CMV and is expressed in certain tumor types (National Cancer Institute, n.d.-a).

ITI-1000 is being tested in a randomized, blinded, and placebo-controlled Phase II study in patients with newly diagnosed GBM that is anticipated to close by 2022.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the ITI-1000 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).

Elaborated details on ITI-1000 regulatory milestones and other development activities have been provided in this report.

The report also highlights the ITI-1000 research and development activities in GBM across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around ITI-1000.

The report contains forecasted sales of ITI-1000 for GBM till 2032.

Comprehensive coverage of the late-stage emerging therapies for GBM.

The report also features the SWOT analysis with analyst views for ITI-1000 in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ITI-1000 Analytical Perspective by DelveInsight

In-depth ITI-1000 Market Assessment

This report provides a detailed market assessment of ITI-1000 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

ITI-1000 Clinical Assessment

The report provides the clinical trials information of ITI-1000 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ITI-1000 dominance.

Other emerging products for GBM are expected to give tough market competition to ITI-1000 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ITI-1000 in GBM.

Our in-depth analysis of the forecasted sales data of ITI-1000 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ITI-1000 in GBM.

Key Questions

What is the product type, route of administration and mechanism of action of ITI-1000?

What is the clinical trial status of the study related to ITI-1000 in glioblastoma multiforme (GBM) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ITI-1000 development?

What are the key designations that have been granted to ITI-1000 for GBM?

What is the forecasted market scenario of ITI-1000 for GBM?

What are the forecasted sales of ITI-1000 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to ITI-1000 for GBM?

Which are the late-stage emerging therapies under development for the treatment of GBM?